Elite Pharmaceuticals (OTCMKTS:ELTP) Shares Cross Below 200-Day Moving Average – Should You Sell?

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP)’s stock price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.55 and traded as low as $0.39. Elite Pharmaceuticals shares last traded at $0.4037, with a volume of 415,016 shares.

Elite Pharmaceuticals Price Performance

The business has a 50-day simple moving average of $0.45 and a two-hundred day simple moving average of $0.55. The company has a quick ratio of 5.44, a current ratio of 7.34 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $434.78 million, a price-to-earnings ratio of 13.46 and a beta of 0.33.

Elite Pharmaceuticals (OTCMKTS:ELTP) last posted its quarterly earnings data on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 EPS for the quarter. The company had revenue of $31.59 million for the quarter. Elite Pharmaceuticals had a return on equity of 47.93% and a net margin of 30.98%.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.